How long does tesamorelin take to work?

Week 26, the first time anyone looked

Both approval trials ran for 26 weeks before the main comparison was made, in adults with HIV and a build-up of fat around the organs.⁴ Here is what the label records at that point:

Every one of those figures belongs to week 26, because that is when the scans were done.¹ The trials did not publish a week-4 or a week-12 reading, so nobody can say from this evidence how much of the change had arrived by either point. A seller who quotes a first month is not quoting these trials.

The second study in the sequence opens by summarizing the first in one line: “Treatment of HIV patients with daily tesamorelin, a growth hormone-releasing factor analogue, for 26 weeks resulted in a significant decrease in visceral adipose tissue (VAT) and improvement in lipids.”² Lipids moved on the same schedule as the fat, which is part of why the change is treated as real rather than as a measurement artifact.

Week 52, and what happened after stopping

At week 26 the trials rerandomized people: some who had been on the drug stayed on it, some switched to placebo, and some who had been on placebo started.² That design is what makes the next year informative. For those who kept going, “The change in VAT was sustained at -18% over 52 weeks of treatment”² — held, rather than deepened. Safety over the extra half-year looked like the first: “The prevalence of adverse events and serious adverse events during the extension phase was comparable with the initial phase.”²

For those who stopped, the finding is a single flat sentence:

The authors put the two halves together in their conclusion: “Though effects on VAT are sustained during treatment for 52 weeks, these effects do not last beyond the duration of treatment.”²

It did not work for everyone

The percentages above are averages across a treated group, and the trials themselves did not treat that group as uniform. A later analysis of 402 people who started on the drug split them by result, using a line drawn before anyone was measured: “those with ≥8% reduction in VAT were defined a priori as responders per the statistical analysis plan”³

Setting that threshold in advance is what makes the split a finding rather than a story told afterward, and the two groups did not look alike at the end. The paper concludes: “In contrast to nonresponders, HIV-infected patients receiving tesamorelin with ≥8% reduction in VAT have significantly improved triglyceride levels, adiponectin levels, and preservation of glucose homeostasis over 52 weeks of treatment.”³

Over longer horizons the same paper sets the scale of the effect: “Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue (VAT) by 15%-20% over 6-12 months in individuals with human immunodeficiency virus (HIV)-associated abdominal adiposity”³ What the drug did to muscle over those same months is on does tesamorelin help build muscle.

Why the half-life has nothing to do with it

Tesamorelin leaves the blood in minutes. Its label puts the elimination half-life at “8 minutes in healthy subjects after single dose subcutaneous administration of the 1.4 mg of EGRIFTA SV”,¹ and the other current label reports “11 minutes in healthy subjects after single dose subcutaneous administration of the 1.28 mg of EGRIFTA WR”.⁵ Five half-lives leave roughly 3% of a dose, so on either figure the molecule is essentially gone within the hour.

None of that is in tension with a six-month result. The drug is a trigger rather than a reservoir: it acts on the pituitary receptor, growth hormone goes up, and growth hormone raises IGF-1, which the trials tracked and found more than 100 ng/mL above baseline at week 26.¹ What takes months is the tissue change downstream, not the clearance of the peptide.

Where that figure sits against the other four molecules is on the axis on the home page, and the half-life calculator does the arithmetic for any interval. The full set of label figures, including the older one people still quote, is on what is tesamorelin.

What the whole evidence base adds up to

A 2026 systematic review pooled the randomized trials and reports its own scope in one line: “Four RCTs (909 patients) were included.”⁶ Its verdict on the effect is short — “Tesamorelin demonstrates efficacy in reducing visceral adiposity in PLWH with lipodystrophy on CART.”⁶ — and so is the qualifier it attaches:

Durability of treatment effects appears in that sentence for the same reason it appears on this page: it is the thing the 52-week extension answered in one direction and nobody has answered in the other. The review also records “Growth hormone-related adverse effects and higher discontinuation rates” on the safety side.⁶

Nine hundred and nine patients, all of them with HIV-associated fat accumulation, is the whole base. Nothing in it describes a healthy adult taking tesamorelin for body composition, which is a different question from whether the drug works.¹ The label’s warnings and who it is ruled out for are on is tesamorelin safe.

Questions that come next

Sources